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We investigated the mRNA expression levels of all six antiapoptotic Bcl-2 subfamily members in 68 human cancer cell lines
using qPCR techniques and measured the ability of known Bcl-2 inhibitors to induce cell death in 36 of the studied tumor cell
lines. Our study reveals that Mcl-1 represents the anti-apoptotic Bcl-2 subfamily member with the highest mRNA levels in the
lung, prostate, breast, ovarian, renal, and glioma cancer cell lines. In leukemia/lymphoma and melanoma cancer cell lines,
Bcl-2 and Bﬂ-1 had the highest levels of mRNA, respectively. The observed correlation between the cell killing properties of
known Bcl-2 inhibitors and the relative mRNA expression levels of anti-apoptotic Bcl-2 proteins provide critical insights into
apoptosis-based anticancer strategies that target Bcl-2 proteins. Our data may explain current challenges of selective Bcl-2
inhibitors in the clinic, given that severe expression of Bcl-2 seems to be limited to leukemia cell lines. Furthermore, our data
suggest that in most cancer types a strategy targeted to Mcl-1 inhibition, or combination of Bﬂ-1 and Mcl-1 inhibition for
melanoma, may prove to be more successful than therapies targeting only Bcl-2.
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Programmed cell death (apoptosis) represents a physiologi-
cal process for removing damaged or infected cells and
maintaining tissue homeostasis.
1 During tumorigenesis,
cancer cells develop the ability to avoid apoptosis through
the upregulation of anti-apoptotic proteins and/or down-
regulation of proapoptotic signaling pathways. Such mea-
sures allow cancer cells to survive even when challenged with
chemotherapeutic or DNA-damaging compounds that would
normally trigger cytotoxic responses. The Bcl-2 (B-cell
lymphoma/leukemia-2) family of both pro- and antiapoptotic
proteins are central regulators of apoptosis. This family of at
least 26 proteins is divided into three groups, or subfamilies,
onthe basisof their functionand the compositionof their Bcl-2
homology (BH) domains.
2
In humans, six antiapoptotic members of the Bcl-2 family
have been identiﬁed (Bcl-2, Bcl-xL, Bcl-B, Bcl-W, Bﬂ-1, and
Mcl-1). These proteins contain a hydrophobic cleft that is able
to bind to BH3-only proteins and to the pro-apoptotic Bcl-2
familymembersBad,Bak,andBaxtoinhibitapoptosis.
3Inthe
absence of this binding, the proapoptotic Bcl-2 members are
recruited to the outer mitochondrial membrane (OMM) at
which they oligomerize and cause OMM permeabilization,
releasing proapoptotic effectors such as SMAC or cyto-
chrome c. The released cytochrome c binds to APAF-1 and
pro-caspase 9 to from the apoptosome, which generates
mature caspase 9 and begins a proteolytic cascade,
ultimately resulting in cell death as shown in Figure 1.
4
Meanwhile, SMAC release antagonizes a class of caspase
inhibitory proteinscalledIAPs (inhibitorofapoptosisproteins),
initiating the apoptotic cascade (Figure 1). Pharmacological
inhibition of antiapoptotic Bcl-2 subfamily members and IAP
proteins in cancer have emerged as major strategies for
allowing intrinsic stress responses to induce apoptosis and
cause tumor regression.
5
Determination of the structure of Bcl-2 and subsequent
identiﬁcation of the BH3-binding cleft has allowed the creation
of small molecule inhibitors targeting the antiapoptotic Bcl-2
subfamily.
6 Thus far, nearly all therapeutic compounds
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www.nature.com/cddistargeting the Bcl-2 family have focused on the inhibition of
Bcl-2 and Bcl-xL, guided by a large number of immunohisto-
chemical (IHC) studies that have shown these proteins to be
upregulated in a variety of tumor types.
7–9 In breast cancer,
these studies observed correlations of Bcl-2 and Mcl-1 with
differing clinical end points while making no deﬁnitive
connections between prognosis and Bcl-xL protein levels.
7,10
Prior studies of CNS tumor samples used IHC and found a
signiﬁcant upregulation of Bcl-2 and Mcl-1 during tumor
progression.
9 Similarly, in a study of renal cancers, 40% of
patient samples had observable Bcl-2 expression levels.
11 In
prostate cancer, prior studies have demonstrated that Bcl-2
overexpression is associated with the progression of prostate
cancer to an androgen-independent form.
12 Further studies
have shown that in the androgen-responsive prostate
cancer line, LNCaP, overexpression of Bcl-2 permits con-
tinued growth in vitro and tumor formation in vivo despite
androgendeprivation.
13AsubsequentIHCinvestigationof64
NOXA PUMA
mitochondria
BAX BAK
Bcl-2
Bcl-xL
Bcl-W
Mcl-1
Bcl-B
Bfl-1
Chemotherapy/radiation
DNA
damage p53
Cyt C
Smac
Small molecule
antagonists
APAF-1 pro-Casp-9
apoptosome
IAP
Caspases 3,6,7
APOPTOSIS
ABT-737
8Q
8J
Figure 1 Mechanism of Bcl-2 antagonists in cell stress response. The overexpression of antiapoptotic Bcl-2 proteins induce cancer cell resistance to stress-induced
apoptosis. Selective inhibition of a subset of the antiapoptotic Bcl-2 subfamily, as is achieved with ABT-737, has provided promising clinical outcomes, but has also been
shown to be overcome through upregulation of Mcl-1 or Bﬂ-1. Pan-active inhibition of all members of the antiapoptotic Bcl-2 subfamily, as is achieved by the Apogossypol
derivative, 8Q, prevents suppression of p53-mediated apoptosis and precludes compound resistance through upregulation of other subfamily members
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Cell Death and Diseaseadenocarcinomas of the prostate found that 25, 100, and 81
percent of the tumor samples exhibited observable levels of
Bcl-2, Bcl-xL, and Mcl-1, respectively.
14 Studies of Bcl-2
family protein levels in colon cancer samples identiﬁed
opposite correlations between patient prognosis and Bcl-2
or Mcl-1 protein levels using IHC.
15,16 Furthermore, IHC
studies of ovarian cancer have recently suggested a more
prominent role for Mcl-1 compared with Bcl-2 or Bcl-xL.
17 As a
group, these studies have provided a ﬁrm foundation for the
developmentanduseofantiapoptoticBcl-2subfamilyinhibitors
in cancer development, but due to their use of mainly patient-
derived samples, they have precluded the ability to perform
additionalstudiesintohowtoimprovecompoundtargetingand/
or to understand why there are highly variable clinical end
points between the different studies, often within the same
cancertype.
18Noneofthesestudies,however,haveexamined
the relative abundance of all six antiapoptotic Bcl-2 subfamily
members in a readily available set of cancer cell lines.
The progression into clinical trials of compounds with
selective activity for Bcl-2 and Bcl-xL has made this issue
especially urgent. For example, several pre-clinical studies
have shown that tumors highly expressing Mcl-1 are typically
resistant to compounds that selectively target Bcl-2 and
Bcl-xL.
19,20 Comprehensive studies into the levels of each of
the antiapoptotic Bcl-2 subfamily members may therefore
allow for better optimization of antiapoptotic Bcl-2 subfamily
inhibitors.
Results
The expression levels of all six antiapoptotic Bcl-2 subfamily
members (Bcl-2, Bcl-xL, Bcl-B, Bcl-W, Bﬂ-1, and Mcl-1) were
studied in 68 human cancer cell lines and in cultured human
dermal ﬁbroblast (HDF) cells using quantitative real-time
polymerase chain reaction (qPCR) techniques. In addition,
control total RNA samples from the brain, cervix, colon,
kidney, lung, melanocyte, ovary, and prostate tissues were
obtained and screened as outlined in the Materials and
Methods section. The average, maximum, and minimum
Ct values were determined and these were then transformed
into initial copy number values, which are charted in Figures 2
and 3. Distributions ofthe expression levels ofthe six genes in
all cell lines are presented in Figure 4. Prior immunohisto-
chemical studies of Bcl-2 and Bcl-xL protein levels in breast
cancer cell lines,
21 Mcl-1 protein levels in melanoma cell
lines
22 and Bﬂ-1 protein levels in leukemia and lymphoma cell
lines
23 correlate directly with levels observed for each of the
respective cell lines studied in this survey.
Bcl-2 subfamily expression in breast, CNS, colon, lung,
ovarian, prostate, and renal cancer lines. The majority of
solid tumor-derived cell lines displayed similar relative anti-
apoptotic Bcl-2 subfamily expression patterns with Mcl-1
having the highest level of mRNA expression of all Bcl-2
subfamily members (Figures 2 and 3). bcl-xL and bcl-W
mRNAs were also detected at intermediate levels in most cell
lines with Bcl-xL expression levels approaching those of
Mcl-1 in a subset of cell lines in each cancer type. Expression
of Bcl-2, Bﬂ-1, and Bcl-B coding mRNA was observed
primarily at low levels. A number of cell lines throughout
these tissue types have increased mRNA expression of Bﬂ-1
when compared with the primary human dermal ﬁbroblast
(HDF) sample used as a comparator. These include the CNS
cancer cell line LN-229 (15-fold), the non-small cell lung
0.00
0.25
0.50
0.75
1.00
C
o
p
y
 
N
u
m
b
e
r
 
i
n
 
M
i
l
l
i
o
n
s Colon Cancer Cell Lines
0.00
0.25
0.50
0.75
1.00
C
o
p
y
 
N
u
m
b
e
r
 
i
n
 
M
i
l
l
i
o
n
s Leukemia Cancer Cell Lines
0.00
0.25
0.50
0.75
1.00
C
o
p
y
 
N
u
m
b
e
r
 
i
n
 
M
i
l
l
i
o
n
s
CNS Cancer Cell Lines
Caco-2
KM-12
HT-29
HCT-15
HCT-116
HCC-2998
COLO-205
SW-620
SW-480
BP3
THP-1
RS4;11
RS11846
RPMI-8226
MOLT4
K562
HL-60
T-47D
MCF7
MDA-MB-468
MDA-MB-231
MCF10
HS-578T
BT-549
LN-229
U87
U373
U251
SF539
SF268
Bcl-2 Bcl-xL Bcl-B Bcl-W Bfl1 Mcl1
Breast Cancer Cell Lines
0.00
0.25
0.50
0.75
1.00
C
o
p
y
 
N
u
m
b
e
r
 
i
n
 
M
i
l
l
i
o
n
s
Figure2 ExpressionofthesixantiapoptoticBcl-2subfamilymembersinthebreast,CNS,colon,andleukemiacancercelllines.(a–d)Bargraphsrepresentingtherelative
copynumberofeachBcl-2subfamilymember:Bcl-2inblack,Bcl-xLinorange,Bcl-Bingreen,Bcl-Winblue,Bﬂ1inpurple,andMcl1inred.Celllinesaregroupedaccordingto
their identiﬁed tissue type. Error bars represent S.E.M.
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Cell Death and Diseasecancer lines A549, H1915 and NCI-H522 (12, 16 and 8-fold,
respectively), the prostate cancer cell lines PC-3 and DU-145
(three and ﬁve-fold), and the renal cancer cell line RXF-393
(four-fold). Furthermore, the CNS cancer cell line LN-229, the
lung cancer cell line H460 and the renal cancer cell lines
ACHN, RXF-393, and TK-10 have increased expression of
Bcl-2 when compared with the HDF sample. In addition,
of all 69 lines screened, only Caco-2 had signiﬁcant
overexpression of Bcl-B compared with HDF cells.
Interestingly, the control samples show at least a two-fold
increase in mRNA expression of Bcl-2 in the kidney, lung,
cervix, and ovary tissue and of Bcl-B in the kidney, cervix,
and colon tissue (Supplementary Figure 2).
Bcl-2 subfamily expression in leukemia/lymphoma
cancer lines. The antiapoptotic Bcl-2 subfamily expression
has been highly studied in both leukemia/lymphoma cell lines
and primary cell samples, yet nearly all studies have focused
on the three proteins Bcl-2, Bcl-xL, and Mcl-1.
19 Elevated
levels of Bcl-2 have been correlated with shorter patient
survival and this has lead to the development of a number of
anti-Bcl-2 therapeutics.
24 Meanwhile, increased Mcl-1 has
been correlated with more advanced forms of chronic
lymphocytic leukemia and resistance to both chemotherapy
and Bcl-2 inhibitors.
19,20 Bﬂ-1 has also been reported to be
overexpressed in B-cell lymphoma
23 and is associated with
increased resistance to apoptotic stimulation,
25and treatment
with the Bcl-xL/Bcl-2 antagonist ABT-737.
20,26
Our data demonstrate high levels of Bcl-2 expression in
seven of eight leukemia/lymphoma lines studied (Figure 2d).
Only one cell line, BP3, shows low levels of Bcl-2 expression,
while displaying increased Bﬂ-1 expression, 20-fold higher
than in HDF cells. In addition to Bcl-2, RS11846 cells also
show very high (80-fold) levels of Bﬂ-1 expression compared
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Figure 3 ExpressionofthesixantiapoptoticBcl-2subfamilymembersinthelung,melanoma,ovarian,prostate,andrenalcancercelllines.(a–d)Bargraphsrepresenting
therelativecopynumberof each Bcl-2subfamily member:Bcl-2in black,Bcl-xL in orange,Bcl-Bin green,Bcl-W in blue,Bﬂ1in purple, andMcl1in red.Cell lines are grouped
according to their identiﬁed tissue type. Error bars represent S.E.M.
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Figure4 RangeofantiapoptoticBcl-2subfamilyexpression.(a–c)BoxandWhiskerplotofthe10–90thpercentileoftherelativecopynumberdistributionacrossall68cell
lines studies (a), the 8 leukemia cell lines (b), or the 12 melanoma cell lines (c)
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Cell Death and Diseasewith HDF cells. All eight leukemia/lymphoma lines show
moderate levels of mcl-1, bcl-xL, and bcl-W mRNA. Thus,
leukemiaandlymphomacelllines,morethananyothertypeof
cancer cell line studied, are characterized by a wide diversity
of antiapoptotic Bcl-2 subfamily expression (Figure 4b).
Bcl-2 subfamily expression in melanoma cancer
lines. Bcl-2 subfamily expression studies of melanoma and
melanocytes have identiﬁed that while levels of Bcl-2, Bcl-xL,
and Mcl-1 levels do not vary greatly between the normal and
the cancerous state,
8 Bcl-2 subfamily proteins are highly
expressed in melanoma and a high Bcl-2/Bax ratio has been
found to correlate with increased CD95/Fas-mediated
apoptosis.
27 Furthermore, Mcl-1 and Bcl-xL were found to be
upregulated during melanoma progression and metastases,
whereas Bcl-2 levels were downregulated. Finally, it was
observed that survival of melanoma lines after proteosomal
treatment relies on increased Mcl-1 rather than Bcl-2 protein
expression,
28 suggesting prominent roles for members of the
Bcl-2 subfamily other than Bcl-2 in melanoma.
Our study of 12 melanoma cell lines found that all but one
sample (WM-35) had signiﬁcantly higher Bﬂ-1 expression
than the HDF cells, as well as in all other cancer types
investigated (Po0.0001; Figure 4c, Supplementary Figure
1A). Furthermore, in four of the 12 lines (SK-MEL-28,
SK-MEL-5, UACC-257, and WM-115), Bﬂ-1 was the highest
expressed antiapoptotic Bcl-2 subfamily member. In compar-
ison to HDF cells, the 11 melanoma lines have Bﬂ-1
expression levels of 9–150-fold higher. Interestingly, Bcl-2
expression in all 12 lines also has the highest average
expression for any cancer type other then leukemia
(P¼0.0001; Supplementary Figure 1B). Increased Bﬂ-1
expression was also observed in the total RNA from the
melanocyte control sample with a 50-fold overexpression
compared with the HDF comparator (Supplementary Figure
2). These data agree with the previous studies that found
increased Bcl-2 in melanoma as well as point to other Bcl-2
subfamily members as contributors to apoptosis resistance.
High levels of Bcl-xL, Bcl-W, and Mcl-1 were also observed
across all melanoma lines studied (Figure 4c).
Small molecule Bcl-2 inhibitors. To assess the ability of
the qPCR data to predict sensitivity or resistance to Bcl-2
family antagonists in cell culture, we selected a subset of the
tumor cell lines to be challenged with small molecule
inhibitors of antiapoptotic Bcl-2 family proteins. We tested
ABT-737,
26 which is known to speciﬁcally target Bcl-2, Bcl-xL,
and Bcl-W,
29 as well as two derivatives of the pan-active
Bcl-2 subfamily inhibitor, Apogossypol, which were recently
reported by our laboratories (Figure 5a).
30,31 The IC50 values
for each of these three small molecules tested against the six
antiapoptotic Bcl-2 subfamily members, as determined by
their ability to displace a ﬂuorochrome-conjugated BH3 Bid
peptide, are presented in Table 1.
29,30 These data
demonstrate that the two Apogossypol derivatives have
broader cross-reactivity compared with ABT-737, as 8J is
able to bind to all of the subfamily members except for Bﬂ-1
at a uniform IC50 value of near 1mM, whereas 8Q exhibits
uniform IC50 values for all six members at approximately
1mM. In contrast, although ABT-737 is not active against
Bﬂ-1, Mcl-1, and Bcl-B, it is signiﬁcantly more potent against
the other members as compared with the Apogossypol
derivatives. Hence, these compounds provide research
tools to assess whether it is preferable to have a potent
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Table 1 Fluorescence polarization displacement assay of the three Bcl-2
antagonists to each of the six antiapoptotic Bcl-2 subfamily members
Bcl-xL Bcl-2 Bcl-W Mcl-1 Bcl-B Bﬂ-1
IC50 values (lM)
ABT-737 0.064 0.12 0.024 420 410 420
8J 1.7 0.70 6.1 1.1 5.0 13.1
8Q 0.93 0.67 6.7 0.59 3.0 1.3
A survey of the anti-apoptotic Bcl-2 subfamily expression
WJ Placzek et al
5
Cell Death and Diseaseand sub-class selective inhibitor versus pan-Bcl-2
antagonists with moderate afﬁnities (Table 1).
To validate that the studied compounds act primarily
through the intended mechanism in restoring Bax/Bak-
mediated apoptosis, we used wild-type mouse embryo
ﬁbroblasts (MEFs) versus bax
 / /bak
 /  double knockout
(DKO) genotypes (Figure 5b). Compounds that kill using the
intended mechanism should not show cytotoxic activity on
Bax/Bak DKO cells. We observed that 8J induces Bax/Bak-
dependent cell death with limited off-target cytotoxicity at
concentrations up to 10mM. This agrees with similar ﬁndings
for ABT-737 and 8Q reported previously.
30,32
To determine the ability of each of the compounds toinduce
cell death in 36 selected tumor cell lines (listed in Figure 6a),
we measured cell viability using the ATP-Lite assay (Perkin-
Elmer, Waltham, MA, USA), which assesses levels of cellular
ATPasasurrogateforcellviability.Eachcelllinewascultured
with a range of compound concentrations in triplicate and the
resulting LD50 values were reported (Figure 6a). In six of the
studied cell lines, ABT-737 showed no effect across the
compound concentration range tested. ABT-737 showed
potent cytotoxic activity against leukemia/lymphoma lines,
consistent with the observation that they exhibited signiﬁcant
Bcl-2 expression. Similarly, in those lines with minimal Bcl-2
expression, ABT-737 was found to be the least active of the
three compounds. A positive correlation between log LD50,
[ABT-737] and bcl-2 mRNA copy number was observed with
a correlation coefﬁcient of r¼ 0.7233 (P-value 40.0001;
Figure 6b). Interestingly, no similar correlation between log
LD50, [ABT-737] and bcl-xL or bcl-W mRNA copy number was
observed. Furthermore, as expected from prior literature
that shows that suppression of Mcl-1 via siRNA resulted in
increased ABT-737 effectiveness,
33 we observed that if we
normalized the bcl-2 mRNA level to a uniform mcl-1 mRNA
level across the panel of tumor cell lines, then the correlation
improved to r¼ 0.8081 (P-value 40.0001). Similar normal-
ization of the bcl-2 mRNA level to bcl-xL mRNA levels or to
the sum of all other Bcl-2 subfamily mRNA levels resulted in
r values of  0.7735 or  0.8135, respectively.
The compounds 8Q and 8J had signiﬁcantly smaller
variations in their LD50 ranges across the 36 screened tumor
cell lines (Figure 7) presumably due to their cross-reactivity
with most antiapoptotic Bcl-2 subfamily members. The poor
afﬁnity of 8J for Bﬂ-1 did not seem to impact its affect on
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Figure 6 AbilityofcellstoevadeapoptosisinpresenceofBcl-2inhibitors.(a)LD 50valuesforeachofthethreecompoundsABT-737(bluebars),8J(redbars),and8Q(green
bars) in 36 selected cell lines grouped according to their cancer type are shown. Error bars represent S.E.M. and the asterisks represent cell lines in which ABT-737 showed no
apparent cell killing effect at a concentration of 30mM. (b) Scatter plot of Bcl-2 mRNA copy number and the measured LD50 values for the 36 cell selected cell lines
A survey of the anti-apoptotic Bcl-2 subfamily expression
WJ Placzek et al
6
Cell Death and Diseasemelanoma cell lines, which were observed to have high bﬂ-1
mRNA levels in addition to high mcl-1 mRNA levels. This may
be due to the difference in LD50 values between Bﬂ-1 and the
other family members being only one order of magnitude,
whereas ABT-737 shows more than three orders of magni-
tudeselectionforBcl-2(Table 1)over Bﬂ-1.Notably,thecolon
cancer line HCT-115 presented LD50 values of 415mM for all
three compounds tested and may therefore prove to be an
interesting model for future studies of cancer cells demon-
strating non-Bcl-2 subfamily-mediated resistance to apopto-
sis.
Discussion
In this study, we investigated the expression levels of all six
antiapoptotic Bcl-2 subfamily members at the mRNA level in
68cancercelllinesacrossninebasictissuetypesusingqPCR
techniques. We then measured the ability of chemical Bcl-2
inhibitors to induce cell death in 36 of the studied lines. In
sevenofninetissuetypes,Mcl-1wasexpressedatthehighest
levels among the family members, comprising from 40–60%
of Bcl-2 subfamily mRNA present. Bcl-2 was found to be
prominently expressed in leukemia/lymphoma lines but not in
solid tumor cell lines. Melanoma cell lines and the melanocyte
control sample all signiﬁcantly overexpressed Bﬂ-1 at levels
9–150-fold higher than in HDF reference cells. We then
studied the ability of three previously described Bcl-2
subfamily inhibitors
26,30 to induce cell death in a collection of
the 36 cell lines screened for mRNA copy number.
Although we acknowledge that mRNA levels cannot
deﬁnitely predict protein levels present in a cell, prior studies
of the antiapoptotic Bcl-2 subfamily members protein levels
correlate well with our ﬁndings.
21–23 It has also been shown
that constant turnover of both protein and mRNA levels are
integral parts of Bcl-2 regulation.
34 Moreover, to investigate
the ability of the qPCR data to predict the efﬁcacy of Bcl-2
antagonists, we tested three chemical Bcl-2 inhibitors
(ABT-737, 8Q, and 8J) against a selection of the tumor cell
lines studied. In support of the predictive nature of the mRNA
studies here presented, we found an inverse correlation
(r¼ 0.7344, Po0.0001) between ABT-737-induced LD50
values and bcl-2 mRNA copy number (Figure 6b). Further-
more, this correlation was modulated by Mcl-1 (r¼ 0.8081)
and total antiapoptotic Bcl-2 subfamily (r¼ 0.8135) mRNA
levels, consistent with prior preclinical studies using Mcl-1
knockdown approaches.
20 Interestingly, LD50 values for
ABT-737 did not correlate with either bcl-xL or bcl-W mRNA
expression despite biochemical analysis showing that
ABT-737 has potent nanomolar afﬁnity to these proteins. This
result suggests that either ABT-737 binding to Bcl-xL or Bcl-W
does not result in inhibition of their antiapoptotic functionality,
or these two proteins are not critical for the survival of the
tumorcelllinesstudiedinroutinecultures.However,itmustbe
noted that therapies targeting antiapoptotic Bcl-2 family
proteins may sensitize tumor cells to apoptotic stimuli, such
as chemotherapy or radiation, without displaying single-agent
cytotoxic activity.
A similar, though much weaker correlation was identiﬁed
between observed LD50 values for compound 8J and
calculated bcl-2 mRNA copy number (r¼ 0.4143,
P¼0.01). Given the wider activity across all subfamily
members and the small range of observed LD50, improved
information on the individual importance of each Bcl-2
subfamily member responsible for such a pan-active inhibitor
would require either the discovery of a highly responsive cell
line, development of improved Apogossypol derivatives with
sub-micromolar afﬁnities for individual Bcl-2 subfamily mem-
bers, or intense studies of single cell lines while knocking out
different subfamily members using siRNA techniques. Such
multivariate analysis could prove very informative in the
further optimization of pan-active Bcl-2 subfamily inhibitors. In
contrast, a more broad-spectrum Apogossypol derivative,
8Q, which shows micromolar afﬁnity against all six Bcl-2
subfamily members did not have an observable correlation
between its LD50 values and the mRNA levels of any single
subfamilymember.ThisislikelyduetothesmallrangeofLD50
values observed in the tested cell lines. Nevertheless, the
correlations identiﬁed, especially for ABT-737, demonstrate
the predictive nature of the reported qPCR studies.
Our data support and supplement to some extent results
reported in prior studies focused on single cancer tissue types
that looked at only a subset of the subfamily members (e.g.
Bcl-2, Bcl-xL, or Mcl-1) assessing relative protein levels using
IHC methods. These studies found that for all cancer types,
except leukemia, Mcl-1 is upregulated and can often be
associated with some metric of cancer progression or poor
patient prognosis.
10,15,17 Our data agree with these studies in
as much as mcl-1 mRNA is prominently expressed in most
tumor cell lines. In this regard, it is typical that only the most
aggressive cancers can be established readily as cell lines
that can be easily passaged long-term in culture. Thus, the
striking expression of mcl-1 mRNA observed in established
tumor cell lines may be a reﬂection of their more aggressive
character. In addition, siRNA studies targeting Mcl-1 have
demonstrated that reduction of mcl-1 mRNA levels causes
increased sensitivity to ABT-737
35 and decreased resistance
to anoikis.
22
We must note that qPCR techniques are not able to
differentiate among the posttranslational modiﬁcations of
individual members of the Bcl-2 subfamily at the protein level.
In this regard, it has been reported that signiﬁcant stabilization
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Figure 7 Range of compound LD50 values across the 36 cell lines studied. Box
and Whisker plot of the 10–90th percentile of the measured LD50 values for the
three compounds are represented on a log scale
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Cell Death and Diseaseor proteolysis of Bcl-2 and Mcl-1 protein may be facilitated by
phosphorylation.
36 Furthermore, the turnover of antiapoptotic
Bcl-2 subfamily members has been reported to be dependent
on several other proteins, including the levels of proapoptotic
Bcl-2 subfamily members, the E3 ubiquitin ligase, MULE/
LASU1,orindividualcaspases,tonameafew.
37Althoughthis
is the case, we feel that by presenting a wide survey of the
antiapoptotic Bcl-2 subfamily expression in cancer types this
study will allow more dedicated investigation into these
various control systems. A prior focused study of apoptosis
gene expression in the NCI-60 cells lines only characterized
the expression of Bcl-2 and Bcl-XL using qPCR.
38 It should
also be noted that many of the prior studies were conducted
with primary patient samples that are not readily available
throughout the scientiﬁc community, nor in sufﬁcient quantity
to allow repeated probing for the discernment of LD50 values
in the context of drug optimization programs. Thus, further
development of the Bcl-2 ﬁeld requires the analysis of
available tumor cell lines, which serve as models to reﬁne
knowledge of biochemical signaling pathways and develop
improved antiapoptotic Bcl-2 subfamily-targeted inhibitors.
Owing to the large number of studies already conducted on
the NCI-60 panel of cancer lines, we attempted to include as
many of these cell lines as possible in our analysis.
Asaresultofthisstudy,wefeelthatthecurrentdifﬁcultiesof
Bcl-2-targeted inhibitors in the clinic
39 may be understood
through our observations that the severe upregulation of
Bcl-2/Bcl-xL seems to be isolated to leukemia like cell lines
and that in other cancer types a strategy targeted to Mcl-1
inhibition (or Mcl-1/Bﬂ-1 inhibition in the case of melanoma)
may prove to be more successful. In addition, although
targeting individual members of the antiapoptotic Bcl-2
subfamily may initially prove promising, recent studies with
ABT-737 suggest that resistance to the compound is a
consequence of the ability of cancer cells to adapt and
express other Bcl-2 subfamily members.
20 Thus, the devel-
opment of pan-active Bcl-2 inhibitors may lead to more
successful therapeutic outcomes to be achieved. Our data
illustrates that even within a cancer tissue type signiﬁcant
deviations may be seen between cell lines. Taken together,
these data argue clinical trials seeking to develop Bcl-2
inhibitors should minimally include assessment of the
expression of all six antiapoptotic Bcl-2 subfamily members
so that the activity proﬁle of compounds can be connected
with the repertoire of Bcl-2 family members present within the
tumor of individual patients.
Materials and Methods
Cell lines and total RNA samples. Cell lines used in this study were
assembled through the generosity of research groups at The Burnham Institute for
Medical Research. The cell lines SK-MEL-2, SK-MEL-28, and HS-578T were
acquired from the ATCC. Primary human dermal ﬁbroblast (HDF) cells were
purchased from Cascade Biologics (Invitrogen, Carlsbad, CA, USA). The
FirstChoice Human Total RNA survey panel purchased from Applied Biosystems
(Foster City, CA, USA).
Cell culture. Cell lines included in the NCI-ADS cancercell panel were grown in
RPMI 1640 medium containing 5mM Glutamax (Invitrogen) supplemented with
10% fetal bovine serum (Invitrogen) and 1% antibiotic/antimycotic (Invitrogen). All
other immortalized cell lines were grown in their recommended medium containing
5mMGlutamax(Invitrogen)supplementedwith10%fetalbovineserum(Invitrogen)
and 1% antibiotic/antimycotic (Invitrogen). All cultures were grown at 371Ci na
humidiﬁedincubatorwith 5% CO2. Cells were maintainedat 40–80%conﬂuence for
a minimum of 1 week before RNA extraction. The HDF cells were cultured as
recommended and total RNA was harvested after 6 and 10 phase doublings.
Quantitative PCR. Total RNA from 3 10
6 cells from each line were
collected at 70–80% conﬂuence and prepared using the Illustra RNAspin mini
total RNA extraction kit (GE Healthcare, Piscataway, NJ, USA) according to the
manufacturer’s recommendations for cultured cells. Each RNA sample was
quantiﬁed with a NanoDrop ND-1000 Spectrophotometer and the RNA integrity of
each sample was further conﬁrmed using a BioRad Experion Bioanalyzer (BioRad,
Hercules, CA, USA) to assess the ratio of 28 and 18s RNAs. All samples exhibited
28/18s RNA ratios of 1.8–2.2, which indicates the presence of high-quality total
RNA. The complementary DNA was produced using qScript cDNA Supermix
(Quanta Biosciences, Gaithersburg, MD, USA) according to manufacturer’s
recommendations in 20ml reaction mixtures using 400ng of total RNA as the
template. The resultant cDNA was diluted 1:7 being used in qPCR.
Primers for use in qPCR were identiﬁed from a search of the Quantitative PCR
Primer Database when available or designed using freely available software from
IDT or Invitrogen. Identiﬁed primers were purchased from Invitrogen and tested for
the ampliﬁcation of a single uniform amplicon through analysis of SYBR melting
curves for three of the target cell lines: H460, A549 and H1299. Standard curves
used to transform Ct values to allow absolute quantiﬁcation of the initial cDNA copy
number for each of the genes studied were collected and showed linear
ampliﬁcation over six orders of magnitude, covering the Ct ranges of all included
samples (r40.994). In addition, negative controls for each primer pair were run in
the absence of cDNA template to assure that all readings were the result of the
intendedampliﬁcationreaction. The primersare listed in supplementaryTable1. To
avoid ampliﬁcation of genomic DNA, each primer pair straddled at least one intron/
exon border.
All qPCR reactions were performed in 17ml reaction mixtures containing 2mlo f
the diluted cDNA, 8.5ml PerfeCta SYBR green FastMix, Low ROX (Quanta
Biosciences),1mleachof7.5mMforwardandreverseprimers,and4.5mlmolecular
gradewater.Eachsamplewas run induplicateona 96-wellplatewith theMx3000P
qPCRsystem(Stratagene,LaJolla,CA,USA).Eachplateprobedtheexpressionof
ﬁve variable target cell lines and a constant cDNA preparation of human dermal
ﬁbroblastcells(Invitrogen)forthesixmembersoftheBcl-2subfamily.Eachgroupof
ﬁve target cell lines was run in triplicate against three different reporter genes:
GAPDH,RPIIandb2-microglobulin.Thermocyclingconditionsconsistedof aninitial
polymerase inactivation step at 951C for 10min, followed by 40 cycles at 951C for
30s,551Cfor1min,and721Cfor1min.Afterwards,meltingcurvesweregenerated
to conﬁrm a single uniform peak. Baselines were automatically set by the software
and the threshold was manually set to a single value of 500 for all experiments. A
method of analyzing each resulting ampliﬁcation plot and melting curve, outlined by
Nolan et al.
40, was used to identify any abnormal data that were subsequently
excluded from further analysis.
Calculated Ct values were exported to Microsoft Excel and Graphpad Prism for
further analysis. To control for plate-to-plate variation, data on each plate were
normalized to the Ct values determined for the Mcl-1 standard curve. Each cell
type’s data was further normalized to the average level of mRNA expression
(Ct value) of RPII across all cell lines. The S.E.M. values for the six replicates for
each gene in all 68 cell lines were then calculated from these normalized Ct values
before transformation of the data into initial copy number values. The
average±S.E.M. values were calculated and transformed into initial copy
number values for the purpose of displaying the error bars in graphical
representations of the data.
ATPLite analysis. The activity of three compounds against a selection of the
human cancer cell lines was determined using the ATP-Lite 1-Step assay
(PerkinElmer). All cells were seeded in RPMI 1640 medium with 5mM Glutamax
(Invitrogen) supplemented with 5% fetal bovine serum (Invitrogen) and 1 
antimitotic/antimycotic (Invitrogen). Cells were plated into 96-well plates (Greiner,
Bio-One, Monroe, NC, USA) at varying initial densities in 100ml volumes such that
they would reach 80–90% conﬂuence 4 days after seeding. At 24h after seeding,
the medium of adherent lines was removed and fresh RPMI-1640 medium,
supplemented as above, was added. Compounds were diluted to ﬁnal
concentrations of 30, 10, 4, 1, 0.3, and 0.1mM with 0.1% DMSO and added to
the samples in triplicate. Each sample plate was incubated at 371C in a 5% CO2
environment for 72h. Cell viability was evaluated using ATP-LITE reagent
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Cell Death and Disease(PerkinElmer) and measurements were obtained on a Victor 2030 Explorer
(PerkinElmer). Data were normalized to DMSO control-treated cells and LD50
values were calculated in Graphpad Prism 5.2 (Graphpad Software).
Flourescence polarization assays (FPA) and cell viability
assays. The FPA studies on 8Q and 8J against Bcl-W and Bcl-B were
conducted as previously described.
29
The apoptotic activity of 8J against mouse embryonic ﬁbroblast (MEF) WT cells
and MEF BAX/Bak double-knockout cells (DKO) was assessed by staining with
Annexin V and PI as previously described.
30
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